The Africa Centres for Disease Control and Prevention (Africa CDC) expressed its support for the immediate implementation of measures adopted by the Democratic Republic of Congo (DRC) to contain the growing Ebola outbreak in Bundibugyo.
In a statement released on Monday, the specialized health agency of the African Union highly praised the efforts of the DRC's health authorities, which developed a comprehensive package of 'bold, innovative measures' to localize the outbreak. The agency noted that such national responsibility ensures the necessary autonomy, speed, and accountability for conducting emergency response on a wide scale.
The response measures include mass vaccination and a village-oriented approach aimed at identifying every suspected case and death, as well as ensuring access for every community to protection, medical care, and accurate information.
According to the latest data provided by local health authorities on Tuesday, since the declaration of the 17th Ebola outbreak on May 15, the DRC has registered a total of 4381 confirmed cases and over 2000 deaths.
Africa CDC highlighted the rapid geographical spread of the disease: since May 15, it has increased from 11 health zones in one province to 53 health zones across five provinces of the DRC.
Pointing out that virus transmission is outpacing traditional operations, Africa CDC reported that only about 10% of expected contacts had been accounted for, while approximately four out of five new infections are occurring outside known chains of transmission.
The comprehensive package of measures developed by the DRC government and its partners also covers strengthening humanitarian governance, including the safe resumption of schools, as well as ensuring strong coordination and full financial accountability.
The agency emphasized that the strategic use of the existing vaccine Ervebo—due to its potential cross-protection—is currently the only available vaccination strategy that must be rapidly and widely applied to reduce severe illness and mortality.
The statement noted: 'This recommendation is based on the urgency of the outbreak, the growing, though not yet conclusive, body of evidence for cross-protection, and the established safety profile and availability of Ervebo.'

